The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
Journal
Targeted oncology
Date Issued
2022-04-23
Author(s)
Huang, Yen-Hsiang
Hsu, Kuo-Hsuan
Tseng, Jeng-Sen
Yang, Tsung-Ying
Chen, Kun-Chieh
Chen, Jeremy J W
Chang, Gee-Chen
Abstract
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors are the standard first-line treatment for patients with advanced and recurrent EGFR-positive non-small cell lung cancer.
Subjects
OPEN-LABEL; GEFITINIB; ADENOCARCINOMA; MUTATIONS
SDGs
Publisher
SPRINGER
Type
journal article